Schizophrenia, Positive and Negative symptoms, cognitive symptoms, Inflammatory Factors, Metabolic syndrome Risk Factors, BioZen D. Schizophrenia
Conditions
Interventions
Intervention 1: Intervention group: BioZen D is a combination of natural probiotic product and 400 units of vitamin D? In the form of oral capsules in a package of cans containing 90 capsules, with or
Sponsors
University of social welfare and rehabilitation sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Having Schizophrenia based on DSM-V criteria and by Clinical Psychiatrist Interview Male orFemale Patients in the Age range of 18 to 65 years Having at least a Fifth grade Elementary Education Patients with schizophrenia who are taking Risperidone up to 6 mg per day and take Biperiden in case of Extrapyramidal Complications and 1 mg of Lorazepam in case of Insomnia.
Exclusion criteria
Exclusion criteria: Having a history of Brain Injury or Trauma based on Information in the Patient's file Having Mental Retardation based on the Information in the patient's file History of Opioid or Stimulant Substance use in the last Three months Taking Antidepressant or Stimulant Drugs Having an Allergy history to Probiotics or vitaminD drugs Receiving Antibiotics in 14 days before the Start of the study Pregnancy or Lactation Parkinson's disease based on Clinical Examination or Patient's record
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive symptoms. Timepoint: The beginning of the study then every two weeks until the end of the study. Method of measurement: Positive and Negative Syndrome Scale.;Negative symptoms. Timepoint: The beginning of the study then every two weeks until the end of the study. Method of measurement: Positive and Negative Syndrome Scale.;Cognitive symptoms. Timepoint: The beginning of the study then every two weeks until the end of the study. Method of measurement: Montreal Cognitive Assessment.;Inflammatory factor, c-reactive protein test. Timepoint: Before and after the study. Method of measurement: Blood test.;Inflammatory factor, Erythrocyte sedimentation rate(ESR). Timepoint: Before and after the study. Method of measurement: Blood test.;Metabolic Syndrome Risk Factor, Fasting Blood Sugar. Timepoint: Before and after the study. Method of measurement: Blood Test.;Metabolic Syndrome Risk Factor, Fasting Lipid Profile. Timepoint: Before and after the study. Method of measurement: Blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Difficulty in bowel movement. Timepoint: The beginning of the study then every two weeks until the end of the study. Method of measurement: Ask the patient on a 4-point scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAida Mohammadi
University of social welfare and rehabilitation sciences
Outcome results
None listed